

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Running title: Higher dose corticosteroids for COVID-19

RECOVERY Collaborative Group*

*The Writing Committee and Trial Steering Committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.

Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.

Email: recoverytrial@ndph.ox.ac.uk

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

24 SUMMARY

25 **Background:** Low-dose corticosteroids have been shown to reduce mortality for
26 hypoxic COVID-19 patients requiring oxygen or ventilatory support (non-invasive
27 mechanical ventilation, invasive mechanical ventilation or extra-corporeal membrane
28 oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient
29 group.

30 **Methods:** This randomised, controlled, open-label platform trial (Randomised
31 Evaluation of COVID-19 Therapy [RECOVERY]) is assessing multiple possible
32 treatments in patients hospitalised for COVID-19. Eligible and consenting adult patients
33 with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturation <92%
34 on room air) were randomly allocated (1:1) to either usual care with higher dose
35 corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg once
36 daily for 5 days or until discharge if sooner) or usual standard of care alone (which
37 includes dexamethasone 6 mg once daily for 10 days or until discharge if sooner). The
38 primary outcome was 28-day mortality. On 11 May 2022, the independent Data
39 Monitoring Committee recommended stopping recruitment of patients receiving no
40 oxygen or simple oxygen only to this comparison due to safety concerns. We report the
41 results for these participants only. Recruitment of patients receiving ventilatory support
42 continues. The RECOVERY trial is registered with ISRCTN (50189673) and
43 clinicaltrials.gov (NCT04381936).

44 **Findings:** Between 25 May 2021 and 12 May 2022, 1272 COVID-19 patients with
45 hypoxia and receiving no oxygen (1%) or simple oxygen only (99%) were randomly
46 allocated to receive usual care plus higher dose corticosteroids versus usual care alone

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

47 (of whom 87% received low dose corticosteroids during the follow-up period). Of those
48 randomised, 745 (59%) were in Asia, 512 (40%) in the UK and 15 (1%) in Africa. 248
49 (19%) had diabetes mellitus. Overall, 121 (18%) of 659 patients allocated to higher dose
50 corticosteroids versus 75 (12%) of 613 patients allocated to usual care died within 28
51 days (rate ratio [RR] 1.56; 95% CI 1.18-2.06; $p=0.0020$). There was also an excess of
52 pneumonia reported to be due to non-COVID infection (10% vs. 6%; absolute difference
53 3.7%; 95% CI 0.7-6.6) and an increase in hyperglycaemia requiring increased insulin
54 dose (22% vs. 14%; absolute difference 7.4%; 95% CI 3.2-11.5).

55 **Interpretation:** In patients hospitalised for COVID-19 with clinical hypoxia but requiring
56 either no oxygen or simple oxygen only, higher dose corticosteroids significantly
57 increased the risk of death compared to usual care, which included low dose
58 corticosteroids. The RECOVERY trial continues to assess the effects of higher dose
59 corticosteroids in patients hospitalised with COVID-19 who require non-invasive
60 ventilation, invasive mechanical ventilation or extra-corporeal membrane oxygenation.

61 **Funding:** UK Research and Innovation (Medical Research Council) and National
62 Institute of Health and Care Research (Grant ref: MC_PC_19056), and Wellcome Trust
63 (Grant Ref: 222406/Z/20/Z).

64 **Keywords:** COVID-19, corticosteroid, dexamethasone, mortality, clinical trial.

65

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

66 INTRODUCTION

67 The RECOVERY trial has previously shown that the use of corticosteroids (using
68 dexamethasone 6 mg once daily for ten days or until discharge if sooner) reduces the
69 risk of death in patients admitted to hospital with COVID-19 and hypoxia.¹ Subsequent
70 findings that additional immunosuppression with an interleukin-6 (IL-6) receptor blocker
71 and/or a Janus kinase (JAK) inhibitor further reduces the risk of death in these patients
72 raises the question whether simply increasing the dose of corticosteroid rather than
73 adding other immunomodulators could confer additional benefits at substantially lower
74 cost.^{2,3}

75 Initially, the dose of dexamethasone chosen for the RECOVERY trial was 6 milligrams
76 once daily on the basis that there is considerable experience of using similar doses of
77 corticosteroids safely for exacerbations of asthma and COPD.^{4,5} However, the optimal
78 corticosteroid dose in COVID-19 treatment has not been determined. Higher doses of
79 corticosteroids have been used in non-COVID acute respiratory distress syndrome
80 (ARDS) and in other COVID-19 clinical trials with reported clinical benefit, but these
81 trials have been restricted to severe or critically ill patients and have not directly
82 compared higher doses with the lower dose used in RECOVERY.⁶⁻¹¹ A WHO meta-
83 analysis of randomised controlled trials in critically ill COVID-19 indicated similar
84 mortality benefit with lower and higher-dose corticosteroids, but estimates were
85 imprecise.⁹

86 In April 2021, the United Kingdom COVID-19 Therapeutics Advisory Panel
87 recommended that the RECOVERY trial study higher dose of corticosteroids.¹² The

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

88 RECOVERY trial therefore established a randomised evaluation of the effects of higher-
89 dose corticosteroids versus usual care for adult patients who had been admitted to
90 hospital with COVID-19 and had clinical evidence of hypoxia. Usual care for hypoxic
91 COVID-19 patients includes low dose corticosteroids. On 11 May 2022, the independent
92 Data Monitoring Committee recommended that this comparison be halted for those
93 patients receiving no oxygen or simple oxygen only on the grounds of safety. Here we
94 report the results for these patients. Recruitment to this comparison continues as
95 planned for patients receiving non-invasive ventilation or invasive mechanical
96 ventilation.

97

98 **METHODS**

99 **Study design and participants**

100 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-
101 initiated, individually randomised, controlled, open-label, platform trial to evaluate the
102 effects of potential treatments in patients hospitalised with COVID-19. Details of the trial
103 design and results for other possible treatments (dexamethasone, hydroxychloroquine,
104 lopinavir-ritonavir, azithromycin, tocilizumab, convalescent plasma, colchicine, aspirin,
105 casirivimab plus imdevimab, and baricitinib) have been published previously.^{1-3,13-19} The
106 trial is underway at hospital organisations in the United Kingdom, supported by the
107 National Institute for Health Research Clinical Research Network, as well as in South
108 and Southeast Asia and Africa. Of these, 81 hospitals in the UK, 5 in Nepal, 2 in
109 Indonesia, 2 in Vietnam, 2 in South Africa, and 1 in Ghana enrolled participants in the

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

110 evaluation of higher dose corticosteroids (appendix pp 2-31). The trial is coordinated by
111 the Nuffield Department of Population Health at the University of Oxford (Oxford, UK),
112 the trial sponsor. The trial is conducted in accordance with the principles of the
113 International Conference on Harmonisation–Good Clinical Practice guidelines. The
114 protocol is approved by all relevant regulatory authorities and ethics committees in each
115 participating country (appendix pp 32) The protocol and statistical analysis plan are
116 available in the appendix (pp 71-152) with additional information available on the study
117 website www.recoverytrial.net.

118 Patients aged at least 18 years admitted to hospital were eligible for the study if they
119 had clinically suspected or laboratory confirmed SARS-CoV-2 infection, clinical
120 evidence of hypoxia (i.e. receiving oxygen with or without other forms of respiratory
121 support, or with oxygen saturations <92% on room air) and no medical history that
122 might, in the opinion of the attending clinician, put the patient at significant risk if they
123 were to participate in the trial. Patients were ineligible for the comparison of higher dose
124 corticosteroid vs. usual care if there was a known contra-indication to short-term use of
125 corticosteroids, suspected or confirmed influenza, or current use of nirmatrelvir/ritonavir,
126 ritonavir or other potent CYP3A inhibitors. Endemic infections were screened for as
127 required by local practice. Other immunomodulatory therapies were not contra-indicated
128 but investigators were advised to consider the total burden of such therapy (e.g.
129 combining an IL-6 receptor antagonist with higher dose corticosteroid). Written informed
130 consent was obtained from all patients, or a legal representative if patients were too
131 unwell or unable to provide consent.

132 **Randomisation and masking**

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Higher dose corticosteroids for COVID-19

133 Baseline data were collected using a web-based case report form that included
134 demographics, level of respiratory support, major comorbidities, suitability of the study
135 treatment for a particular patient, SARS-CoV-2 vaccination status, and treatment
136 availability at the study site (appendix pp 44-47).

137 Eligible and consenting patients were assigned in a 1:1 ratio to either usual standard of
138 care plus higher dose corticosteroids or usual standard of care alone (which includes
139 low dose corticosteroids, usually dexamethasone 6 mg once daily for 10 days or until
140 discharge if sooner), using web-based simple (unstratified) randomisation with
141 allocation concealed until after randomisation (appendix pp 42-44).^{20,21} Patients
142 allocated to higher dose corticosteroid were to receive dexamethasone 20 mg daily for 5
143 days followed by dexamethasone 10 mg for 5 days (or until discharge if sooner).
144 Alternative corticosteroid regimens for pregnant women are described in the protocol
145 (appendix p 78).

146 As a platform trial, and in a factorial design, patients could be simultaneously
147 randomised to other treatment groups: i) empagliflozin versus usual care, ii) sotrovimab
148 versus usual care, and iii) molnupiravir versus usual care. Further details of when these
149 factorial randomisations were open are provided in the supplementary appendix (p 42-
150 44). Participants and local study staff were not masked to the allocated treatment. The
151 Trial Steering Committee, investigators, and all other individuals involved in the trial are
152 masked to outcome data while recruitment and 28-day follow-up are ongoing.

153 **Procedures**

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

154 An online follow-up form was completed by site staff when patients were discharged,
155 had died, or at 28 days after randomisation, whichever occurred first (appendix pp 48-
156 56). Information was recorded on adherence to allocated trial treatment, receipt of other
157 COVID-19 treatments, duration of admission, receipt of respiratory or renal support,
158 new cardiac arrhythmia, thrombosis, clinically significant bleeding, non-COVID infection,
159 metabolic complications (collected from 28 July 2021 onwards), and vital status
160 (including cause of death). In addition, in the UK, routinely collected healthcare and
161 registry data were obtained, including information on vital status at day 28 (with date
162 and cause of death); discharge from hospital; and receipt of respiratory support or renal
163 replacement therapy. For sites outside the UK a further case report form (appendix p
164 58) collected vital status at day 28 (if not already reported on follow-up form).

165 **Outcomes**

166 Outcomes were assessed at 28 days after randomisation, with further analyses
167 specified at 6 months. The primary outcome was 28-day all-cause mortality. Secondary
168 outcomes were time to discharge from hospital, and, among patients not on invasive
169 mechanical ventilation at randomisation, the composite outcome of invasive mechanical
170 ventilation (including extra-corporeal membrane oxygenation) or death. Prespecified
171 subsidiary clinical outcomes were use of invasive or non-invasive ventilation among
172 patients not on any ventilation at randomisation, and use of renal dialysis or
173 haemofiltration among patients not receiving such treatment at randomisation.
174 Prespecified safety outcomes were cause-specific mortality, major cardiac arrhythmia,
175 thrombotic and major bleeding events, other infections and metabolic complications.
176 Information on suspected serious adverse reactions was collected in an expedited

Higher dose corticosteroids for COVID-19

177 fashion to comply with regulatory requirements. Details of the methods used to
178 ascertain and derive outcomes are provided in the appendix (pp.153-176).

179 **Sample size and role of the independent Data Monitoring Committee**

180 As stated in the protocol, appropriate sample sizes could not be estimated when the trial
181 was being planned. However, the intention for this comparison was to continue
182 recruitment until sufficient primary outcomes had accrued to have 90% power to detect
183 a proportional risk reduction of 20% at $2P=0.01$.

184 The independent Data Monitoring Committee reviewed unblinded analyses of the study
185 data and any other information considered relevant to the trial at intervals of around 2-3
186 months (depending on speed of enrolment) and was charged with determining if, in their
187 view, the randomised comparisons in the study provided evidence on mortality that was
188 strong enough (with a range of uncertainty around the results that was narrow enough)
189 to affect national and global treatment strategies (appendix p 59).

190 On 11 May 2022, the Data Monitoring Committee recommended stopping recruitment to
191 the higher dose corticosteroid comparison for patients who require no oxygen or simple
192 oxygen only at randomisation due to safety concerns (appendix p 60). The Data
193 Monitoring Committee encouraged continuing recruitment of all those patients who, at
194 randomisation, require either non-invasive ventilation, invasive mechanical ventilation or
195 ECMO.

196 On 13 May 2022, recruitment of patients on oxygen or simple oxygen only to this
197 comparison was stopped, investigators were notified and advised not to administer

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

198 further higher dose corticosteroids to this group as part of the trial. Follow-up of all
199 patients continued as planned. The regulatory authorities and ethics committees in each
200 participating country were notified. Trial procedures were changed as an urgent safety
201 measure and the protocol was subsequently modified and approved accordingly.
202 Recruitment and follow-up of patients receiving non-invasive ventilation or invasive
203 mechanical ventilation remains open.

204 **Statistical Analysis**

205 All analyses were limited to the subgroup of patients on no or simple oxygen at
206 randomization. For all outcomes, intention-to-treat analyses compared patients
207 randomised to higher dose corticosteroids with patients randomised to usual care. For
208 the primary outcome of 28-day mortality, the log-rank observed minus expected statistic
209 and its variance were used to both test the null hypothesis of equal survival curves (i.e.,
210 the log-rank test) and to calculate the one-step estimate of the average mortality rate
211 ratio. We constructed Kaplan-Meier survival curves to display cumulative mortality over
212 the 28-day period. We used the same method to analyse time to hospital discharge with
213 patients who died in hospital right-censored on day 29. Median time to discharge was
214 derived from Kaplan-Meier estimates. For the composite secondary outcome of
215 progression to invasive mechanical ventilation or death within 28 days, and the
216 subsidiary clinical outcomes of receipt of ventilation and use of haemodialysis or
217 haemofiltration, the precise dates were not available and so the risk ratio was estimated
218 instead. Estimates of rate and risk ratios (both denoted RR) are shown with 95%

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

219 confidence intervals. For the primary outcome of 28-day mortality, a sensitivity analysis
220 adjusted for age was done using Cox regression.

221 Since the analyses presented here relate only to the subset of participants who were on
222 no oxygen or simple oxygen only at randomisation, any analyses of the primary
223 outcome in further subgroups defined by different baseline characteristics must be
224 considered exploratory in nature. With that caveat, we present analyses of the primary
225 outcome by age, sex, ethnicity, days since symptom onset, and place of recruitment
226 (UK, elsewhere) with tests of heterogeneity or trend, as appropriate. We have not
227 presented analyses by subgroups for the secondary or other outcomes. Results for the
228 pre-specified other clinical outcomes and safety outcomes are presented. The full
229 database is held by the study team which collected the data from study sites and
230 performed the analyses at the Nuffield Department of Population Health, University of
231 Oxford (Oxford, UK). Analyses were performed using SAS version 9.4 and R version
232 4.0.3. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov
233 (NCT04381936).

234 **Role of the funding source**

235 The funders of the study had no role in study design, data collection, data analysis, data
236 interpretation, or writing of the report. The corresponding authors had full access to all
237 the data in the study and had final responsibility for the decision to submit for
238 publication.

239

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

240 **RESULTS**

241 Recruitment to the evaluation of higher dose corticosteroids commenced on 25 May
242 2021 outside the UK and 29 December 2021 in the UK (following closure of the
243 baricitinib comparison) and ended worldwide for those on no oxygen or simple oxygen
244 on 13 May 2022 following the Data Monitoring Committee recommendation.³ Of 1680
245 patients enrolled in this comparison during this period, 1272 patients on no oxygen or
246 simple oxygen only are included in this evaluation. Of these, 659 were randomly
247 allocated to higher dose corticosteroids and 613 patients were randomly allocated to
248 usual care (Figure 1). The mean age of these participants was 61.1 years (SD 17.5)
249 (webtable 1) with those randomly allocated to higher dose corticosteroids on average
250 1.9 years younger than those allocated usual care group (Table 1). 745 (59%) were in
251 Asia, 512 (40%) in the UK, and 15 (1%) in Africa. 248 (19%) had a history of diabetes
252 mellitus, and 1264 (99%) were receiving simple oxygen (webtable 1).

253 The follow-up form was completed for 657 (99.7%) patients in the higher dose
254 corticosteroid group and 608 (99.2%) patients in the usual care group. Among patients
255 with a completed follow-up form, 91% allocated to higher dose corticosteroid were
256 reported to have received higher dose corticosteroids compared with 1% allocated to
257 usual care (figure 1, webtable 2). Among those with a completed follow-up form
258 allocated usual care, 87% received low dose dexamethasone. Use of other treatments
259 for COVID-19 was broadly similar among patients allocated higher dose corticosteroids
260 and among those allocated usual care, with two-fifths receiving remdesivir and one-
261 tenth receiving an interleukin-6 antagonist during the follow-up period (webtable 2).

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

262 Primary and secondary outcome data are known for >99% of randomly assigned
263 patients. Allocation to higher dose corticosteroids was associated with a significant
264 increase in the primary outcome of 28-day mortality compared with usual care alone:
265 121 (18%) of 659 patients in the higher dose corticosteroid group died vs 75 (12%) of
266 613 patients in the usual care group (rate ratio 1.56; 95% CI 1.18–2.06; p=0.0020; table
267 2, figure 2). A similar proportional risk increase was seen in analyses restricted to
268 participants with a positive SARS-CoV-2 PCR test (RR 1.63, 95% CI 1.22-2.17,
269 p=0.0008) or adjusted for baseline age (RR 1.59, 95% CI 1.19-2.12, p=0.0017). In
270 exploratory analyses, the proportional effect of higher dose corticosteroids on mortality
271 was consistent across all 5 pre-specified subgroups (all interaction p-values ≥ 0.10 ;
272 Figure 3), including by region of recruitment and by ethnicity.

273 Discharge alive within 28 days was similar among those allocated to higher dose
274 corticosteroids compared with usual care (80% vs. 82%; rate ratio 0.92, 95% CI 0.81 to
275 1.04; median 9 days [IQR 5 to 17] vs. 9 days [IQR 5 to 16]) (table 2; webfigure 1).
276 Allocation to higher dose corticosteroids was associated with a higher risk of
277 progressing to the composite secondary outcome of invasive mechanical ventilation or
278 death (20% vs. 13%, risk ratio 1.50, 95% CI 1.16 to 1.94) (table 2; webfigure 2). There
279 were no significant differences in use of ventilation or receipt of haemodialysis or
280 haemofiltration (table 2).

281 Three quarters of the deaths within 28 days were attributed to COVID-19 (webtable 3).
282 Allocation to higher dose corticosteroids was associated with an increase in pneumonia
283 reported as not due to COVID-19 (10% vs. 6%, absolute risk increase 3.7%, 95% CI 0.7
284 to 6.6; webtable 4), but there were no significant differences in the rates of other

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

285 presentations of non-coronavirus infection, new onset cardiac arrhythmia, thrombotic
286 events, or clinically significant bleeding (webtable 4). Allocation to higher dose
287 corticosteroids was associated with an increase in clinically significant hyperglycaemia
288 (ketoacidosis, hyperglycaemic hyperosmolar state, or hyperglycaemia requiring new
289 use of insulin) occurring in 22% vs. 14% participants (absolute risk increase 7.4%, 95%
290 CI 3.2 to 11.5) (webtable 4). There were 37 reports (among 24 participants) of a serious
291 adverse reaction believed to be related to treatment with higher dose corticosteroids
292 (webtable 5), including 15 reports of a serious non-COVID infection, 9 with
293 hyperglycaemia and 5 with gastro-intestinal bleeding.

294

295 **DISCUSSION**

296 In this large, randomised trial, allocation to higher dose corticosteroids significantly
297 increased 28-day mortality for those patients with hypoxia requiring simple oxygen (or
298 no oxygen). There was also an increase in the risk of pneumonia due to non-COVID-19
299 causes and in hyperglycaemic episodes requiring new use of insulin. This hazard
300 appeared similar among patients from the UK and from Asia and Africa, where the
301 prevalence of TB, HIV and other infections is greater. Within five days of receiving the
302 DMC recommendation regarding the hazard associated with higher dose corticosteroids
303 in this patient group, we had notified all investigators and relevant regulatory authorities
304 and ethics committees, including the US Food and Drugs Administration, the European
305 Medicines Agency, and the World Health Organization, and made the information
306 publicly available via our public website.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

307 Strengths of the RECOVERY trial are that it is randomised, has a large sample size,
308 broad eligibility criteria and more than 99% of patients in this analysis have been
309 followed up for the primary outcome. It was also conducted in areas with high (South
310 and Southeast Asia, Africa) and low (UK) prevalence of HIV, TB, and other infections.
311 The study has some limitations: this randomised trial is open label (i.e., participants and
312 local hospital staff are aware of the assigned treatment), however, the outcome of death
313 is unambiguous. Information on radiological, virological or physiological outcomes was
314 not collected. Only about 10% of participants in this evaluation of high-dose
315 corticosteroids received an interleukin-6 antagonist or baricitinib so we are unable to
316 assess any possible interactions between corticosteroid dose and other
317 immunomodulatory treatments. The enrolment of patients on no oxygen or simple
318 oxygen was closed early on the basis of an interim analysis by the independent Data
319 Monitoring Committee. Consequently, it is possible that the size of the hazards
320 presented may be an over-estimate of the true effects of higher dose corticosteroids.²²

321 Prior to the COVID-19 pandemic, the role of corticosteroids in acute lung injury was
322 unclear.²³ This began to change when the RECOVERY trial showed a clear reduction in
323 28 days mortality with the use of 6mg dexamethasone once daily for up to 10 days in
324 COVID-19 patients requiring oxygen therapy.¹ The benefit of corticosteroids amongst
325 critically ill COVID-19 patients was subsequently confirmed in other randomized
326 controlled trials and in a meta-analysis.^{9,24} A broader meta-analysis of the effects of
327 corticosteroids in both COVID-related ARDS and non-COVID ARDS has reported that
328 corticosteroids probably reduce mortality in patients with ARDS regardless of the
329 aetiology.²⁵

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Higher dose corticosteroids for COVID-19

330 Previous difficulties in determining the role of corticosteroids in acute lung injury may
331 have arisen because the benefits and hazards of their use may vary by dose, co-
332 morbidities, and the severity of lung injury (which is reflected in the level of respiratory
333 support required).^{25,26} The initial dexamethasone result from RECOVERY showed a
334 clear difference in effect of low-dose corticosteroids by disease severity (p value for
335 trend <0.001), with the greatest benefit seen in the most severely ill. 28-day mortality
336 was reduced by about one-third in those requiring invasive mechanical ventilation or
337 ECMO, with a more modest reduction of one-fifth in those requiring simple oxygen or
338 non-invasive ventilation, and no benefit observed in those not requiring oxygen.¹

339 The results we present in this paper show that in hypoxic COVID-19 patients who
340 require only simply oxygen therapy, a higher dose of corticosteroids (dexamethasone
341 20 mg once daily for 5 days followed by 10 mg once daily for 5 days or until discharge if
342 sooner) is harmful compared to usual care (which included use of lower dose
343 corticosteroids). However, it remains an open question whether increasing the dose of
344 corticosteroids above 6mg dexamethasone per day is helpful for COVID-19 patients
345 requiring non-invasive or invasive mechanical ventilation – the RECOVERY trial
346 continues to seek an answer for that question.

347 In summary, this large, randomised trial demonstrates that, compared to standard dose
348 corticosteroids, use of higher dose corticosteroids increases mortality for hypoxic
349 patients with COVID-19 who are not receiving non-invasive or invasive mechanical
350 ventilation.

351

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

352 **Research in context**

353 **Evidence before this study**

354 We searched MEDLINE, Embase, MexRxiv and the WHO International Clinical Trials
355 Registry Platform between Sept 1, 2019, and Nov 23, 2022 for randomised controlled
356 trials comparing the effect of different doses of systemic corticosteroids in patients
357 hospitalised with COVID-19 receiving no or simple oxygen at randomisation, using the
358 search terms (Coronavirus infection OR SARS-CoV-2 OR SARS-CoV2 OR SARSCoV2
359 OR COVID OR COVID-19 OR COVID19 OR 2019-nCoV OR Coronavirus or
360 Coronavirinae) AND (corticosteroid OR dexamethasone OR glucocorticoid OR steroid
361 OR hydrocortisone OR methylprednisolone OR prednisolone OR betamethasone) and
362 using validated filters to select for randomised controlled trials. No language restrictions
363 were applied.

364 We identified twelve relevant randomised trials with results available that assessed
365 different doses of corticosteroids in hospitalised COVID-19 patients, at least some of
366 whom were receiving simple oxygen therapy at randomisation: six assessed higher
367 dose dexamethasone (12-24 mg per day) and six assessed methylprednisolone (60-
368 1000 mg per day), all compared to lower dose dexamethasone (6-8 mg per day).²⁷⁻³⁸
369 Four of the trials included only a non-critically ill population and the remainder included
370 a mixed illness severity population.^{28,31,37,38} Eleven of the trials have been fully
371 published of which five were considered to have low risk of bias for the 28-day mortality
372 outcome and six having some concerns (including lack of information about
373 randomisation process, lack of information about prespecified analyses, crossover
374 between randomised groups and post-randomisation exclusion of patients in the

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Higher dose corticosteroids for COVID-19

375 analysis population) (appendix p31). All but one of the trials have found no statistically
376 significant difference in mortality between the treatment groups. The exception was a
377 small trial comparing methylprednisolone (2mg/kg/day for 3 days then 1mg/kg/day for 3
378 days) with dexamethasone (8mg daily for 10 days) that included 140 patients and 18
379 deaths, that reported that methylprednisolone was associated with significantly
380 improved mortality at 10 days.³⁸ There was no information in the trial report about the
381 randomisation process or whether the trial was analysed as pre-specified, conferring
382 some concerns over risk of bias.

383 **Added value of this study:**

384 The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is the largest
385 randomised trial of the effect of different doses of corticosteroids in patients hospitalised
386 with COVID-19 and included patients from 3 continents. We found that among hypoxic
387 patients on simple or no oxygen, randomisation to higher dose corticosteroids
388 (dexamethasone 20 mg daily for 5 days followed by dexamethasone 10 mg for 5 days,
389 or until discharge if sooner) vs. usual care (which included dexamethasone 6 mg once
390 daily in 87% of participants) resulted in an increased risk of all-cause mortality, Overall,
391 121 (18%) of 659 patients allocated to higher dose corticosteroids versus 75 (12%) of
392 613 patients allocated to usual care died within 28 days (rate ratio [RR] 1.56; 95% CI
393 1.18-2.06; p=0.0020). There was also an excess of pneumonia reported to be due to
394 non-COVID infection (10% vs. 6%; absolute difference 3.7%; 95% CI 0.7-6.6) and an
395 increase in hyperglycaemia requiring increased insulin dose (22% vs. 14%; absolute
396 difference 7.4%; 95% CI 3.2-11.5).

397

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Higher dose corticosteroids for COVID-19

398

399 **Implications of all the available evidence:**

400 Among hospitalised patients with COVID-19 who require oxygen or ventilatory support,
401 low-dose corticosteroids reduce the risk of death. However, among those requiring
402 simple oxygen only, higher doses of corticosteroids increase the risk of death compared
403 to low-dose corticosteroids. It remains unclear whether using a higher dose of
404 corticosteroids is beneficial among those requiring non-invasive or invasive ventilation –
405 the RECOVERY trial continues to study this question.

406

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

407 **Contributors**

408 This manuscript was initially drafted by the PWH and MJL, further developed by the
409 Writing Committee, and approved by all members of the Trial Steering Committee. PWH
410 and MJL vouch for the data and analyses, and for the fidelity of this report to the study
411 protocol and data analysis plan. PWH, BB, RLH, JA, JKB, MB, LCC, JD, SNF, TJ, EJ,
412 KJ, WSL, MM, AMo, AMu, KR, GT, RH, and MJL designed the trial and study protocol.
413 MM, LP, MC, G P-A, EK, MR, RKJ, NTP, US, DP, PNT, NN, ES, LM, RS, and the Data
414 Linkage team at the RECOVERY Coordinating Centre, and the Health Records and
415 Local Clinical Centre staff listed in the appendix collected the data. NS and JRE had
416 access to the study data and did the statistical analysis. All authors contributed to data
417 interpretation and critical review and revision of the manuscript. PWH and MJL had
418 access to the study data and had final responsibility for the decision to submit for
419 publication.

420 **Writing Committee (on behalf of the RECOVERY Collaborative Group):**

421 Peter W Horby,* Jonathan R Emberson,* Buddha Basnyat,* Mark Campbell, Leon Peto,
422 Guilherme Pessoa-Amorim, Natalie Staplin, Raph L Hamers, John Amuasi, Jeremy Nel,
423 Evelyne Kestelyn, Manisha Rawal, Roshan Kumar Jha, Nguyen Thanh Phong, Uun
424 Samardi, Damodar Paudel, Pham Ngoc Thach, Nasronudin Nasronudin, Emma
425 Stratton, Louise Mew, Rahul Sarkar, J Kenneth Baillie, Maya H Buch, Jeremy Day, Saul
426 N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim,
427 Marion Mafham, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites,+
428 Richard Haynes,+ Martin J Landray.+

429 * PWH, JRE and BB made an equal contribution

430 + GT, RH and MJL made an equal contribution

431 **Data Monitoring Committee**

432 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo,
433 Mohammed Munavvar, Adilia Warris, Janet Wittes.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

434

435 **Declaration of interests**

436 The authors have no conflict of interest or financial relationships relevant to the
437 submitted work to disclose. No form of payment was given to anyone to produce the
438 manuscript. All authors have completed and submitted the ICMJE Form for Disclosure
439 of Potential Conflicts of Interest. The Nuffield Department of Population Health at the
440 University of Oxford has a staff policy of not accepting honoraria or consultancy fees
441 directly or indirectly from industry (see [https://www.ndph.ox.ac.uk/files/about/ndph-](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)
442 [independence-of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

443 **Data sharing**

444 The protocol, consent form, statistical analysis plan, definition & derivation of clinical
445 characteristics & outcomes, training materials, regulatory documents, and other relevant
446 study materials are available online at www.recoverytrial.net. As described in the
447 protocol, the Trial Steering Committee will facilitate the use of the study data and
448 approval will not be unreasonably withheld. Deidentified participant data will be made
449 available to bona fide researchers registered with an appropriate institution within 3
450 months of publication. However, the Steering Committee will need to be satisfied that
451 any proposed publication is of high quality, honours the commitments made to the study
452 participants in the consent documentation and ethical approvals, and is compliant with
453 relevant legal and regulatory requirements (e.g. relating to data protection and privacy).
454 The Steering Committee will have the right to review and comment on any draft
455 manuscripts prior to publication. Data will be made available in line with the policy and
456 procedures described at: <https://www.ndph.ox.ac.uk/data-access>. Those wishing to
457 request access should complete the form at
458 https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx
459 and e-mailed to: data.access@ndph.ox.ac.uk

460

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

461 **Acknowledgements**

462 Above all, we would like to thank the thousands of patients who participated in this trial.
463 We would also like to thank the many doctors, nurses, pharmacists, other allied health
464 professionals, and research administrators at participating hospital organisations.
465 Supported in the UK by staff at the National Institute of Health and Care Research
466 (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department
467 of Health & Social Care, the Intensive Care National Audit & Research Centre, Public
468 Health Scotland, National Records Service of Scotland, the Secure Anonymised
469 Information Linkage (SAIL) at University of Swansea, and the NHS in England,
470 Scotland, Wales and Northern Ireland.

471 The RECOVERY trial is supported by grants to the University of Oxford from UK
472 Research and Innovation (UKRI) and NIHR (MC_PC_19056), the Wellcome Trust
473 (Grant Ref: 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by
474 core funding provided by the NIHR Oxford Biomedical Research Centre, the Wellcome
475 Trust, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth and
476 Development Office, Health Data Research UK, the Medical Research Council
477 Population Health Research Unit, the NIHR Health Protection Unit in Emerging and
478 Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by
479 a grant from UK Medical Research Council (MC_UU_00002/14). WSL is supported by
480 core funding provided by NIHR Nottingham Biomedical Research Centre. Tocilizumab,
481 casirivimab and imdevimab, sotrovimab, and empagliflozin were provided through
482 support from Roche, Regeneron, GSK, and Boehringer Ingelheim, respectively.
483 Colchicine for use in Indonesia was provided by Combiphar. The views expressed in
484 this publication are those of the authors and not necessarily those of the NHS, the NIHR
485 or the Department of Health and Social Care. For the purpose of Open Access, the
486 author has applied a CC BY public copyright licence to any Author Accepted Manuscript
487 version arising from this submission.

488

It is made available under a [CC-BY 4.0 International license](#) .
Higher dose corticosteroids for COVID-19

Higher dose corticosteroids for COVID-19

490 References

- 491 1. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in
492 Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**(8): 693-704.
- 493 2. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital
494 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
495 *Lancet* 2021; **397**(10285): 1637-45.
- 496 3. RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with
497 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and
498 updated meta-analysis. *Lancet* 2022; **400**(10349): 359-68.
- 499 4. National Institute for Health and Care Excellence. Chronic obstructive pulmonary
500 disease in over 16s: diagnosis and management. 2019.
501 [https://www.nice.org.uk/guidance/ng115/chapter/Recommendations#systemic-](https://www.nice.org.uk/guidance/ng115/chapter/Recommendations#systemic-corticosteroids)
502 [corticosteroids](https://www.nice.org.uk/guidance/ng115/chapter/Recommendations#systemic-corticosteroids) (accessed 16 September 2022 2022).
- 503 5. National Institute for Health and Care Excellence. Oral corticosteroids for
504 asthma. 2022. [https://cks.nice.org.uk/topics/asthma/prescribing-information/oral-](https://cks.nice.org.uk/topics/asthma/prescribing-information/oral-corticosteroids/)
505 [corticosteroids/](https://cks.nice.org.uk/topics/asthma/prescribing-information/oral-corticosteroids/) (accessed 16 September 2022).
- 506 6. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days
507 Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory
508 Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA* 2020;
509 **324**(13): 1307-16.
- 510 7. Dequin PF, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day
511 Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A
512 Randomized Clinical Trial. *JAMA* 2020; **324**(13): 1298-306.
- 513 8. Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and
514 Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19
515 Corticosteroid Domain Randomized Clinical Trial. *JAMA* 2020; **324**(13): 1317-29.
- 516 9. WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Sterne
517 JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids
518 and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA* 2020;
519 **324**(13): 1330-41.
- 520 10. Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute
521 respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir*
522 *Med* 2020; **8**(3): 267-76.
- 523 11. Edalatfard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse
524 as a treatment for hospitalised severe COVID-19 patients: results from a randomised
525 controlled clinical trial. *Eur Respir J* 2020; **56**(6).

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

- 526 12. UK Research and Innovation. 13 April 2021 UK-CTAP: record of decisions. 2021.
527 [https://www.ukri.org/publications/uk-covid-19-therapeutics-advisory-panel-records-of-](https://www.ukri.org/publications/uk-covid-19-therapeutics-advisory-panel-records-of-decisions/13-april-2021-uk-ctap-record-of-decisions/)
528 [decisions/13-april-2021-uk-ctap-record-of-decisions/](https://www.ukri.org/publications/uk-covid-19-therapeutics-advisory-panel-records-of-decisions/13-april-2021-uk-ctap-record-of-decisions/) (accessed 16 September 2022).
- 529 13. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of
530 Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020;
531 **383**(21): 2030-40.
- 532 14. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-
533 ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,
534 controlled, open-label, platform trial. *Lancet* 2020; **396**(10259): 1345-52.
- 535 15. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital
536 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
537 *Lancet* 2021; **397**(10274): 605-12.
- 538 16. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to
539 hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform
540 trial. *Lancet* 2021; **397**(10289): 2049-59.
- 541 17. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with
542 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The*
543 *Lancet Respiratory Medicine* 2021.
- 544 18. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with
545 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*
546 2022; **399**(10320): 143-51.
- 547 19. RECOVERY Collaborative Group. Casirivimab and imdevimab in patients
548 admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-
549 label, platform trial. *Lancet* 2022; **399**(10325): 665-76.
- 550 20. World Health Organization. Update to living WHO guideline on drugs for covid-
551 19. *BMJ* 2021; **372**: n860.
- 552 21. National Institute for Health and Care Excellence. COVID-19 rapid guideline:
553 Managing COVID-19., 2022.
- 554 22. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit
555 and estimation of treatment effects: systematic review and meta-regression analysis.
556 *JAMA* 2010; **303**(12): 1180-7.
- 557 23. Mokra D, Mikolka P, Kosutova P, Mokry J. Corticosteroids in Acute Lung Injury:
558 The Dilemma Continues. *Int J Mol Sci* 2019; **20**(19).
- 559 24. Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope
560 During the Pandemic. *JAMA* 2020.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .
Higher dose corticosteroids for COVID-19

- 561 25. Chaudhuri D, Sasaki K, Karkar A, et al. Corticosteroids in COVID-19 and non-
562 COVID-19 ARDS: a systematic review and meta-analysis. *Intensive Care Med* 2021;
563 **47**(5): 521-37.
- 564 26. Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W.
565 Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated
566 Cochrane Systematic Review and Meta-analysis. *Crit Care Med* 2020; **48**(2): e98-e106.
- 567 27. Group CST, Munch MW, Myatra SN, et al. Effect of 12 mg vs 6 mg of
568 Dexamethasone on the Number of Days Alive Without Life Support in Adults With
569 COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. *JAMA*
570 2021; **326**(18): 1807-17.
- 571 28. Toroghi N, Abbasian L, Nourian A, et al. Comparing efficacy and safety of
572 different doses of dexamethasone in the treatment of COVID-19: a three-arm
573 randomized clinical trial. *Pharmacol Rep* 2022; **74**(1): 229-40.
- 574 29. Montalvan E, Carcamo B, Palacion D, et al. High-dose vs low-dose
575 dexamethasone in patients with COVID-19 in a tertiary hospital in western Honduras.
576 *Chest* 2021; **160**(4): A1117-A8.
- 577 30. Bouadma L, Mekontso-Dessap A, Burdet C, et al. High-Dose Dexamethasone
578 and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19
579 Acute Hypoxemic Respiratory Failure: The COVIDICUS Randomized Clinical Trial.
580 *JAMA Internal Medicine* 2022.
- 581 31. Taboada M, Rodriguez N, Varela PM, et al. Effect of high versus low dose of
582 dexamethasone on clinical worsening in patients hospitalised with moderate or severe
583 COVID-19 pneumonia: an open-label, randomised clinical trial. *Eur Respir J* 2022;
584 **60**(2).
- 585 32. Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or
586 dexamethasone, which one is superior corticosteroid in the treatment of hospitalized
587 COVID-19 patients: a triple-blinded randomized controlled trial. *BMC Infect Dis* 2021;
588 **21**(1): 337.
- 589 33. Salvarani C, Massari M, Costantini M, et al. Intravenous methylprednisolone
590 pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind,
591 randomised, placebo-controlled trial. *Eur Respir J* 2022.
- 592 34. Dastena ZH, Bahadori A, Dehghani M, Asadi-Samani M, Izadi I, Shahraki HR.
593 Comparison of the effect of intravenous dexamethasone and methylprednisolone on the
594 treatment of hospitalized patients with COVID-19: A randomized clinical trial. *Int J Infect*
595 *Dis* 2022; **122**: 659-64.
- 596 35. Wu H, Daouk S, Kebbe J, Chaudry F, Harper J, Brown B. Low-dose versus high-
597 dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A
598 randomized clinical trial. *PLoS one* 2022; **17**(10): e0275217.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Higher dose corticosteroids for COVID-19

- 599 36. Salton F, Confalonieri P, Centanni S, et al. Prolonged higher dose
600 methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a
601 randomised controlled trial (MEDEAS). *The European respiratory journal* 2022; **10**.
- 602 37. Corral-Gudino L, Cuascovich I, Martin-Gonzalez JI, et al. Effect of intravenous
603 pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalised
604 adults with severe COVID-19 pneumonia: An open-label randomised trial. *European*
605 *Journal of Clinical Investigation*: e13881.
- 606 38. Gautam PB, Kumar A, Kannoja BL, Chaudhary R. A comparative study of the
607 efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe
608 COVID-19 disease. *Asian Journal of Medical Sciences* 2021; **12**(12): 17-22.
- 609

Table 1: Baseline characteristics by treatment allocation

	Treatment allocation	
	High dose (n=659)	Low dose (n=613)
Age, years	60.2 (18.3)	62.1 (16.6)
<70	426 (65%)	395 (64%)
≥70 to <80	128 (19%)	122 (20%)
≥80	105 (16%)	96 (16%)
Sex		
Male	393 (60%)	376 (61%)
Female	266 (40%)	236 (38%)
Country		
Ghana	1 (<0.5%)	0 (0%)
Indonesia	41 (6%)	31 (5%)
Nepal	317 (48%)	288 (47%)
South Africa	11 (2%)	3 (<0.5%)
Vietnam	40 (6%)	28 (5%)
United Kingdom	249 (38%)	263 (43%)
Ethnicity		
White	220 (33%)	222 (36%)
Black	6 (1%)	8 (1%)
Asian	363 (55%)	325 (53%)
Other	2 (<0.5%)	7 (1%)
Unknown	68 (10%)	51 (8%)
Number of days since symptom onset	7 (4-10)	7 (4-10)
Number of days since admission to hospital	1 (0-2)	1 (1-3)
Respiratory support received		
None	5 (1%)	3 (<0.5%)
Simple oxygen	654 (99%)	610 (100%)
Previous diseases		
Diabetes	129 (20%)	119 (19%)
Heart disease	186 (28%)	165 (27%)
Chronic lung disease	135 (20%)	134 (22%)
Tuberculosis	5 (1%)	5 (1%)
HIV	3 (<0.5%)	3 (<0.5%)
Severe liver disease *	5 (1%)	7 (1%)
Severe kidney impairment †	22 (3%)	18 (3%)
Any of the above	338 (51%)	307 (50%)
SARS-CoV-2 PCR test result		
Positive	623 (95%)	581 (95%)
Negative	5 (1%)	4 (1%)
Unknown	31 (5%)	28 (5%)
Received a COVID-19 vaccine	358 (54%)	317 (52%)
Use of other treatments		
Remdesivir	221 (34%)	206 (34%)
Tocilizumab	57 (9%)	46 (8%)
Plan to use tocilizumab within the next 24 hours	26 (4%)	26 (4%)

Data are mean (SD), n (%), or median (IQR). 3 pregnant women were randomised. * Defined as requiring ongoing specialist care. † Defined as estimated glomerular filtration rate <30 mL/min per 1.73 m²

Table 2: Effect of allocation to higher dose corticosteroid on key study outcomes

	Treatment allocation		RR (95% CI)
	High dose steroids (n=659)	Usual care (n=613)	
Primary outcome			
28-day mortality	121 (18.4%)	75 (12.2%)	1.56 (1.18-2.06)
Secondary and other key outcomes			
Median duration of hospitalization, days	9 (5 to 17)	9 (5 to 16)	
Discharged from hospital alive within 28 days	527 (80.0%)	505 (82.4%)	0.92 (0.81-1.04)
Invasive mechanical ventilation or death within 28 days	129 (19.6%)	80 (13.1%)	1.50 (1.16-1.94)
Use of ventilation	119 (18.1%)	84 (13.7%)	1.32 (1.02-1.70)
Non-invasive ventilation	108 (16.4%)	82 (13.4%)	1.23 (0.94-1.60)
Invasive mechanical ventilation	22 (3.3%)	14 (2.3%)	1.46 (0.75-2.83)
Renal replacement therapy (RRT) *	12/659 (1.8%)	8/613 (1.3%)	1.40 (0.57-3.39)

Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for other outcomes. CI=confidence interval. * Analyses exclude those on haemodialysis or haemofiltration at randomisation.

Figures

Figure 1: Trial profile

ITT=intention to treat. Higher dose corticosteroid unavailable and higher dose corticosteroid considered unsuitable are not mutually exclusive. High risk patients are those that were receiving non-invasive ventilation, invasive mechanical ventilation or ECMO at randomisation. Low risk patients are those that were hypoxic but receiving no oxygen or simple oxygen only. * Number recruited overall during period that participants on no oxygen or simple oxygen only could be recruited into the higher dose corticosteroid comparison.

Figure 2: Effect of allocation to higher dose corticosteroids or usual care (lower dose corticosteroids) on 28-day mortality in patients receiving no oxygen or simple oxygen only

RR = rate ratio

Figure 3: Effect of allocation to higher dose corticosteroids or usual care (lower dose corticosteroids) on 28-day mortality in patients receiving no oxygen or simple oxygen only by other baseline characteristics.

Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% CIs. The days since onset subgroup excludes those with missing data, but these patients are included in the overall summary diamond. RR=rate ratio.

Figure 1: Trial profile

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.16.22283578>; this version posted December 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).





Figure 2: Effect of allocation to high dose steroids vs usual care on 28-day mortality in patients receiving no oxygen or simple oxygen only

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.16.22283578>; this version posted December 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .



Number at risk	0	7	14	21	28
High dose steroids	659	617	572	545	536
Usual care	613	590	565	547	535

Figure 3: Effect of allocation to high dose steroids vs usual care on 28-day mortality in patients receiving no oxygen or simple oxygen only, by other baseline characteristics

